MOTS-C: The Mitochondrial Peptide That Mimics Exercise
MOTS-C activates AMPK — the same metabolic switch exercise turns on. Learn how this mitochondrial peptide optimizes metabolism, insulin sensitivity, and fat oxidation.
What Is MOTS-C?
MOTS-C (Mitochondrial Open Reading Frame of the 12S rRNA Type-C) is a mitochondrial-derived peptide discovered in 2015 by researchers at the University of Southern California. Published in Cell Metabolism, the discovery revealed that mitochondria produce signaling peptides that regulate metabolism throughout the body — a finding that reshaped our understanding of how cells communicate about energy.
MOTS-C is sometimes described as "exercise in a syringe" because it activates AMPK (AMP-activated protein kinase) — the same master metabolic switch that physical exercise turns on. AMPK activation triggers a cascade of metabolic benefits including improved glucose uptake, enhanced fatty acid oxidation, increased insulin sensitivity, and improved mitochondrial function.
Search interest in MOTS-C has grown 340% year over year as the longevity community recognizes its potential as a metabolic optimization compound. It pairs particularly well with other longevity peptides and serves as a metabolic amplifier in several of our curated protocols.
AMPK: The Master Metabolic Switch
Understanding MOTS-C requires understanding AMPK, the enzyme it activates.
AMPK functions as a cellular energy sensor. When cellular energy is low — during exercise, fasting, or caloric restriction — AMPK activates and shifts the cell from energy storage mode to energy utilization mode. It promotes glucose uptake into cells, increases fatty acid oxidation (fat burning), stimulates mitochondrial biogenesis (creation of new mitochondria), suppresses lipogenesis (fat storage), and enhances insulin sensitivity.
AMPK activation is one of the most well-established pathways in longevity research. Metformin, the most studied longevity drug, works primarily through AMPK activation. Exercise — the single most robust longevity intervention — works partly through AMPK.
MOTS-C activates AMPK through a pathway distinct from both exercise and metformin, meaning its effects can stack with both. A person who exercises, takes metformin, and uses MOTS-C is activating AMPK through three independent pathways simultaneously.
Metabolic Benefits
Improved insulin sensitivity is the most well-documented metabolic effect. MOTS-C enhances glucose uptake into skeletal muscle cells, reducing blood glucose levels and decreasing the amount of insulin needed to maintain normal glucose homeostasis. For individuals with insulin resistance or metabolic syndrome, this is a meaningful clinical benefit.
Enhanced fat oxidation occurs as AMPK shifts cellular metabolism toward burning stored fat for energy. Users frequently report a gradual decrease in body fat percentage, particularly visceral fat, over 8-12 weeks of consistent use.
Exercise performance enhancement has been observed in preclinical studies, where MOTS-C-treated subjects showed improved exercise capacity and endurance. While MOTS-C is not a substitute for exercise, it may amplify the metabolic benefits of physical activity.
Mitochondrial function improvement occurs through AMPK-mediated stimulation of mitochondrial biogenesis. More mitochondria with better function means more efficient energy production at the cellular level — translating to improved physical and cognitive performance.
Protection against metabolic stress has been demonstrated in research showing MOTS-C protects cells from high-fat-diet-induced metabolic dysfunction and age-related metabolic decline.
Dosing
MOTS-C is administered subcutaneously, typically 3 times per week.
The standard dose is 5mg per injection, administered Monday, Wednesday, and Friday (or any 3 non-consecutive days). Some protocols use 10mg twice weekly as an alternative schedule.
Unlike Ipamorelin, MOTS-C does not require empty-stomach timing. It can be administered at any time of day, though morning dosing is common to align with the metabolic demands of the day ahead.
Protocol duration varies by goal. For metabolic optimization, ongoing use is typical. For body recomposition phases, 12-24 week cycles with breaks are common. Your physician will customize the schedule based on your metabolic labs and goals.
Research
The landmark MOTS-C paper was published in Cell Metabolism in 2015 by Dr. Changhan David Lee and colleagues at USC. The study demonstrated that MOTS-C regulates metabolic homeostasis and prevents age-dependent and high-fat-diet-induced insulin resistance in mouse models.
Subsequent research has explored MOTS-C’s effects on exercise physiology, demonstrating improved physical performance and endurance capacity. Studies have also examined its role in preventing age-related metabolic decline.
The research base is growing rapidly, with new studies examining MOTS-C’s potential applications in type 2 diabetes, obesity, metabolic syndrome, and age-related metabolic dysfunction.
Protocols
At Longevity AI, MOTS-C features across multiple protocol combinations. The Longevity Stack pairs it with CJC-1295 + Ipamorelin for comprehensive longevity support. The Metabolic Optimization protocol pairs it with Retatrutide + NMN for maximum metabolic impact. Explore all 100 compounds in our Compound Wiki and use the Dose Calculator to plan your stack.
Take the Health Quiz to see which MOTS-C protocol matches your goals.